Please assess the completion status of the following clinical trial:

Trial Title: Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the Penis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must provide written informed consent~* Eastern Cooperative Oncology Group performance status of at least 1~* Cytologically or histologically proven diagnosis of SCC of the penis~* Uni- or bidimensionally measurable disease as defined by RECIST v1.1 criteria~* Clinical stage N2-3 and/or M1 (TNM 2002)~* Locoregional relapse after prior major surgery/ies (either single or multiple)~* No prior systemic therapy except for the administration of vincristine-bleomycin-methotrexate (VBM) chemotherapy for superficial disease if administered at least 6 months prior to study enrollment~* Adequate bone marrow, liver and renal function~Exclusion Criteria:~* Central nervous system (CNS) metastases or leptomeningeal carcinomatosis~* History of active serious cardiovascular, cerebrovascular, pulmonary co-morbidities~* Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma or any cancer curatively treated \> 5 years prior to study entry.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Dacomitinib (PF-00299804) (Type: EXPERIMENTAL): PF-299804 will be administered orally at a dose of 45 mg/day continuously until surgery, evidence of disease progression or onset of unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).